Dong-A Socio Holdings Co., Ltd. (KRX:000640)

Market Cap	606.53B -4.4%
Revenue (ttm)	1.43T +7.2%
Net Income	90.94B +56.7%
EPS	13,718.29 +56.8%
Shares Out	6.63M
PE Ratio	6.67
Forward PE	6.97
Dividend	1,650.49 (1.77%)
Ex-Dividend Date	Mar 11, 2026

Volume	12,015
Average Volume	14,652
Open	93,900
Previous Close	91,500
Day's Range	93,200 - 95,700
52-Week Range	91,400 - 121,845
Beta	0.11
RSI	27.83
Earnings Date	Apr 29, 2026

About Dong-A Socio Holdings

Dong-A Socio Holdings Co., Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical tri...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 5,653
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 000640

Financial Performance

In 2025, Dong-A Socio Holdings's revenue was 1.43 trillion, an increase of 7.24% compared to the previous year's 1.33 trillion. Earnings were 90.94 billion, an increase of 56.74%.